Adopting an international drug reference pricing scheme would limit drug innovation—potentially leading to higher, not lower, health care costs in the future—while at the same time reducing U.S. biopharmaceutical industry competitiveness, meaning fewer jobs and exports.
Testimonies & Filings
December 31, 2018
Comments to the Centers for Medicare & Medicaid Services on an International Pricing Index Model for Medicare Part B Drugs
December 17, 2018
Comments to the U.S. International Trade Commission Regarding the United States-Mexico-Canada Agreement
Building on NAFTA, the USMCA provides the framework for a more integrated regional economy that is based on innovation, digital technologies, and intellectual property.
December 13, 2018
ITIF submitted comments to the Bureau of Industry and Security in response to an advance notice of proposed rulemaking regarding extending export controls to “emerging and foundational technologies” (EFTs).
November 8, 2018
Comments to the National Telecommunications and Information Administration on Advancing Consumer Privacy and Protecting Innovation
ITIF submitted comments in response to the National Telecommunications and Information Administration’s (NTIA) request for comment (RFC) on the administration’s approach to advancing consumer privacy while protecting prosperity and innovation.
October 29, 2018
Comments to the Federal Communications Commission Supporting Expanding the Flexible Use of the 3.7 to 4.2 GHz Band
ITIF supports market-based solution to quickly transition 3.7 to 4.2 GHz mid-band spectrum to terrestrial mobile use.
October 25, 2018
NITRD’s National AI R&D Strategic Plan is a valuable opportunity to help the United States maintain its competitive edge in the absence of a broader national AI strategy.
October 18, 2018
Amicus Curiae Brief in the U.S. Court of Appeals for the DC Circuit in Support of Respondents in Mozilla v. FCC
ITIF argued in an amicus brief that strong public policy justifications supported the FCC’s change of course in its Restoring Internet Freedom order.
September 26, 2018
Testimony Before House Oversight IT Subcommittee on Ensuring America Remains the World Leader in Technology and Innovation
In testimony before the House Oversight Subcommittee on Information Technology, Rob Atkinson stated that there are steps Congress should take to help roll back Chinese innovation mercantilism and ensure the United States remains the world leader in technology and innovation.
September 24, 2018
Petition to the Food and Drug Administration Requesting a Stop to Deceptive and Misleading “Non-GMO” Food Labels
The Non-GMO Project food label deliberately deceives and misleads consumers in violation of the Federal Food, Drug and Cosmetic Act. ITIF petitions FDA to prohibit such labels.
September 17, 2018
ITIF supports the merger of Sprint and T-Mobile, as it would help accelerate 5G deployment, improve market structure, and intensify competition.